1. Home
  2. CASS vs ALT Comparison

CASS vs ALT Comparison

Compare CASS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cass Information Systems Inc

CASS

Cass Information Systems Inc

HOLD

Current Price

$43.25

Market Cap

571.1M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.88

Market Cap

576.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASS
ALT
Founded
1906
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.1M
576.0M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CASS
ALT
Price
$43.25
$3.88
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$45.50
$16.33
AVG Volume (30 Days)
101.1K
4.5M
Earning Date
01-22-2026
11-06-2025
Dividend Yield
2.95%
N/A
EPS Growth
37.29
N/A
EPS
2.31
N/A
Revenue
$222,318,000.00
$20,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.33
N/A
P/E Ratio
$21.36
N/A
Revenue Growth
7.50
N/A
52 Week Low
$36.08
$2.90
52 Week High
$47.00
$8.75

Technical Indicators

Market Signals
Indicator
CASS
ALT
Relative Strength Index (RSI) 55.81 31.76
Support Level $43.37 $4.92
Resistance Level $45.25 $5.37
Average True Range (ATR) 1.00 0.42
MACD -0.01 -0.15
Stochastic Oscillator 46.81 1.36

Price Performance

Historical Comparison
CASS
ALT

About CASS Cass Information Systems Inc

Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: